New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
09:07 EDTCMRXChimerix appoints M. Michelle Berrey, M.D., M.P.H. as CEO
Chimerix announced the appointment of M. Michelle Berrey, M.D., M.P.H. to the position of President and CEO. Dr. Berrey succeeds Kenneth I. Moch following his resignation from that role to pursue other interests. In addition, Dr. Berrey will continue to serve as Chimerix's Chief Medical Officer.
News For CMRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
18:43 EDTCMRXChimerix 3.65M share Secondary priced at $29.00
Morgan Stanley and JPMorgan acted as joint book running managers for the offering.
October 29, 2014
17:00 EDTCMRXChimerix announces commencement of $105M common stock offering
Morgan Stanley and JP Morgan are acting as joint book-running managers for the offering, and Cowen and Company, Piper Jaffray and Stifel Nicolaus are acting as co-lead managers for the offering.
16:26 EDTCMRXChimerix files $150M common stock shelf
Subscribe for More Information
October 27, 2014
18:05 EDTCMRXNYC boy with Ebola-like symptoms tests negative for disease, WSJ says
Subscribe for More Information
11:24 EDTCMRXNovavax rises after announcing Ebola vaccine development program
Subscribe for More Information
07:27 EDTCMRXYoung NYC boy tested for Ebola, NY Post reports
Subscribe for More Information
October 26, 2014
14:40 EDTCMRXFDA issues Emergency Use Authorization for Ebola diagnostic tests
Subscribe for More Information
October 24, 2014
10:55 EDTCMRXDallas nurse now Ebola virus free, to be released, NBC reports
NBC and other media outlets cites NIH on Nina Pham's release. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED). Reference Link
October 23, 2014
15:25 EDTCMRXNew York confirms health care worker being tested for Ebola
Subscribe for More Information
14:58 EDTCMRXNew York doctor rushed to hospital with Ebola-like symptoms, NY Post reports
Subscribe for More Information
06:22 EDTCMRXEU to boost Ebola research with EUR 24.4M
The European Commission has today announced EUR 24.4M from the EU budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, the EU research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative. The funding will be provided following proposals from teams across the EU and in numerous 3rd countries, which were evaluated by an independent group of experts. The Commission has also asked the European and Developing Countries Clinical Trials Partnership to include emerging epidemics of concern to Africa, including Ebola, in its work plan. This will allow to fund clinical trials on drugs, vaccines and diagnostics in upcoming calls. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
October 22, 2014
06:41 EDTCMRXWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
October 20, 2014
09:09 EDTCMRXEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
October 19, 2014
16:44 EDTCMRXEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTCMRXCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTCMRXBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTCMRXSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 16, 2014
11:48 EDTCMRXChimerix highlights FDA Ebola authorization, adds potential product candidate
Subscribe for More Information
08:49 EDTCMRXChimerix price target raised to $45 from $27 at William Blair
William Blair raised its price target for Chimerix shares to $45 after the company held a research and development update event. The firm added to its model brincidofovir sales for the treatment of adenovirus and says the opportunity to develop a treatment for Ebola represents potentially substantial upside to its estimates and valuation. The firm reiterates an Outperform rating on Chimerix.
07:08 EDTCMRXChimerix price target raised to $39 from $33 at Cantor
Cantor raised its price target on Chimerix after the company's Brincidofovir drug cut the death rate of patients with Adenovirus in half. The firm thinks the company is on track to file for approval of the drug in early 2016, and it keeps a Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use